Results 61 to 70 of about 2,182,415 (399)

Randomized, Controlled Trial of the Long Term Safety, Immunogenicity and Efficacy of RTS,S/AS02(D) Malaria Vaccine in Infants Living in a Malaria-Endemic Region. [PDF]

, 2013
The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization.
A Olotu, Ali Mohammed, Amanda Leach, B Lell, David Schellenberg, E Macete, EV Macete, Francisca Machera, Grace Mwangoka, Hassan Mshinda, J Sacarlal, J Sacarlal, JJ Aponte, Joe Cohen, Johan Vekemans, KA Bojang, KE Kester, KP Asante, Marc Lievens, Marcel Tanner, Marie-Claude Dubois, MedDRA, MT White, Mwanajaa Shomari, Nahya Salim, Omar Juma, P Aide, P Aide, P Bejon, Richard Kamata, S Abdulla, S Owusu-Agyei, Salim Abdulla, ST Agnandji, ST Agnandji, ST Agnandji, Sulende Kubhoja, Terrell Carter, Thomas Aebi, Tonya Villafana, W Ripley Ballou, WHO, WHO, WHO/IVR   +43 more
core   +5 more sources

O-Acetylation is essential for functional antibody generation against Staphylococcus aureus capsular polysaccharide

Human Vaccines & Immunotherapeutics, 2018
Staphylococcus aureus produces an antiphagocytic polysaccharide capsule to evade neutrophil-mediated killing. Many vaccines against encapsulated bacterial pathogens require generation of functional anti-capsular antibodies to mediate protection against ...
Ingrid L. Scully, Viliam Pavliak, Yekaterina Timofeyeva, Yongdong Liu, Christine Singer, Annaliesa S. Anderson   +5 more
doaj   +1 more source

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Science, 2021
Description Antibody levels predict vaccine efficacy Symptomatic COVID-19 infection can be prevented by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.
P. Gilbert, D. Montefiori, A. McDermott, Y. Fong, D. Benkeser, Wei-zhi Deng, Honghong Zhou, Christopher R. Houchens, Karen Martins, L. Jayashankar, F. Castellino, B. Flach, Bob C. Lin, S. O'connell, C. McDanal, Amanda Eaton, M. Sarzotti-Kelsoe, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars van der Laan, N. Hejazi, C. Huynh, Jacqueline Miller, Hana M. El Sahly, L. Baden, Mira Baron, Luis I. De La Cruz, C. Gay, Spyros A. Kalams, Colleen F. Kelley, M. Andrasik, J. Kublin, L. Corey, K. Neuzil, Lindsay N. Carpp, R. Pajon, D. Follmann, R. Donis, R. Koup   +39 more
semanticscholar   +1 more source

Vaccine hesitancy: Beliefs and barriers associated with COVID‐19 vaccination among Egyptian medical students

Journal of Medical Virology, 2021
Vaccine hesitancy poses serious challenges for achieving coverage for population immunity. It is necessary to achieve high COVID‐19 vaccination acceptance rates and medical students’ coverage as future health care providers.
Shimaa M. Saied, E. Saied, I. Kabbash, Sanaa A Abdo   +3 more
semanticscholar   +1 more source

Genomic variations associated with attenuation in Mycobacterium avium subsp paratuberculosis vaccine strains [PDF]

, 2013
BACKGROUND: Mycobacterium avium subspecies paratuberculosis (MAP) whole cell vaccines have been widely used tools in the control of Johne's disease in animals despite being unable to provide complete protection. Current vaccine strains derive from stocks
Bull, TJ, Greene, M, Linedale, R, McKendrick, IJ, Sales, J, Schock, A, Sharp, JM, Stevenson, K   +7 more
core   +1 more source

Meningococcal serogroup B vaccines: Estimating breadth of coverage

Human Vaccines & Immunotherapeutics, 2017
Neisseria meningitidis serogroup B (MenB) is an important cause of invasive meningococcal disease. The development of safe and effective vaccines with activity across the diversity of MenB strains has been challenging.
Robert G. K. Donald, Julio Cesar Hawkins, Li Hao, Paul Liberator, Thomas R. Jones, Shannon L. Harris, John L. Perez, Joseph J. Eiden, Kathrin U. Jansen, Annaliesa S. Anderson   +9 more
doaj   +1 more source

Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center

npj Vaccines, 2021
The RV144 HIV-1 vaccine trial has been the only clinical trial to date that has shown any degree of efficacy and associated with the presence of vaccine-elicited HIV-1 envelope-specific binding antibody and CD4+ T-cell responses.
Leila Eslamizar, Constantinos Petrovas, David J. Leggat, Kathryn Furr, Michelle L. Lifton, Gail Levine, Steven Ma, Christopher Fletez-Brant, Wesley Hoyland, Madhu Prabhakaran, Sandeep Narpala, Kristin Boswell, Takuya Yamamoto, Hua-Xin Liao, David Pickup, Elizabeth Ramsburg, Laura Sutherland, Adrian McDermott, Mario Roederer, David Montefiori, Richard A. Koup, Barton F. Haynes, Norman L. Letvin, Sampa Santra   +23 more
doaj   +1 more source

Conducting a phase III clinical trial in children during the COVID- 19 pandemic: Experience and lessons learnt from a clinical research facility of Nepal

Human Vaccines & Immunotherapeutics, 2023
Clinical trials in humans are vital to test safety and efficacy of new interventions and are accompanied with the complexity of related regulatory guidelines, stringent time frame and financial burden particularly when participants are children ...
Ram Hari Chapagain, Jessica Maharjan, Santosh Adhikari, Prabhat Thapa, Kshitij Kunwar, Bishnu Rath Giri, Nisha Jyoti Shrestha, Anil Kumar Shrestha, Sanjeet Kumar Shrestha, Suresh Man Tamang, Haeun Cho, Eun Lyeong Park, Jiyoung Lee, Jinae Lee, Deok Ryun Kim, Jae Seung Yang, Tarun Saluja, Anh Wartel, Julia Lynch, Katerina Rok Song   +19 more
doaj   +1 more source

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.

Journal of the American Medical Association (JAMA), 2021
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients In contrast to immunocompetent participants in vaccine trials,1,2 a low proportion (17%) of solid organ transplant recipients mounted a positive antibody ...
B. Boyarsky, William Werbel, R. Avery, A. Tobian, A. Massie, D. Segev, J. Garonzik‐Wang   +6 more
semanticscholar   +1 more source

Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines [PDF]

, 2014
BackgroundPolymorphism in antigens is a common mechanism for immune evasion used by many important pathogens, and presents major challenges in vaccine development.
Anders, Robin F., Barry, Alyssa E., Beeson, James G., Cross, Nadia J., Drew, Damien R., Dutta, Sheetij, Elliott, Salenna R., Hodder, Anthony N., Marsh, Kevin, Mueller, Ivo, Mugyenyi, Cleopatra K., Osier, Faith, Richards, Jack S., Senn, Nicolas, Siba, Peter M., Stanisic, Danielle I., Terheggen, Ulrich   +16 more
core   +1 more source